Health outcomes of patients with acute coronary syndromes prescribed ticagrelor in UK primary care: a retrospective cohort study (Outcomes in UK ACS patients prescribed ticagrelor)

Study identification

• EU PAS number:
  EUPAS17107
• Study ID:
  30120
• Official title and acronym:
  Health outcomes of patients with acute coronary syndromes prescribed ticagrelor in UK primary care: a retrospective cohort study (Outcomes in UK ACS patients prescribed ticagrelor)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  Retrospective cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015, following ACS. Patient baseline characteristics will be described: (Age, Gender, Body Mass Index, Smoking status, Sociodemographic status), type of ACS and interventions, CV history and comorbidities, bleeding and respiratory history.The following outcomes will be examined: Incidence of vascular events (composite MI, Stroke, vascular death, specific vascular event and all cause death), incidence of bleeding and incidence of dyspnoea. Time to event for vascular events, bleeding and dyspnoea.
• Study status:
  Finalised

Research institutions and networks

Institutions

AstraZeneca

Study timelines

Date when funding contract was signed

Planned: 12/12/2014

Actual: 15/01/2015

Study start date

Planned: 25/02/2016

Actual: 25/02/2016

Data analysis start date

Planned: 31/03/2015

Actual: 31/03/2015

Date of final study report

Planned: 30/05/2018

Actual: 14/03/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

D5130R00027